- Lipocine Announces Financial Results For The Year Ended December 31, 2020
- Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference
- Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis
- Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
- Lipocine to Present at Two Upcoming Investor Conferences
- Lipocine Closes Underwritten Public Offering Of Common Stock
- Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock
- Lipocine Announces Launch Of Public Offering Of Common Stock
More ▼
Key statistics
On Tuesday, Lipocine Inc (LPCN:NAQ) closed at 1.41, 187.76% above the 52 week low of 0.49 set on Apr 20, 2020.
52-week range
Markit short selling activity
Open | 1.40 |
---|---|
High | 1.43 |
Low | 1.34 |
Bid | 1.38 |
Offer | 1.40 |
Previous close | 1.39 |
Average volume | 1.19m |
---|---|
Shares outstanding | 88.29m |
Free float | 79.94m |
P/E (TTM) | -- |
Market cap | 122.72m USD |
EPS (TTM) | -0.4017 USD |
Data delayed at least 15 minutes, as of Apr 20 2021 21:00 BST.
More ▼